文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植后无病生存2年患者的生存与晚期死亡分析

Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation.
PubMed 文献 · Br J Haematol · 2023-06-12

本研究纳入2007至2019年在本中心接受allo-HSCT后无病生存满2年的831例血液恶性肿瘤患者,其中508例(61.1%)接受单倍体相合供者移植。10年总生存率为91.9%(95%CI 89.8-93.5),既往III-IV级急性GVHD(HR 2.98)和严重慢性GVHD(HR 3.60)影响生存。10年晚期复发概率8.7%,非复发死亡概率3.6%,晚期死亡首位原因为复发(49.0%)。

要点

  • 移植后无病生存2年者10年总生存率达91.9%(95%CI 89.8-93.5)
  • III-IV级急性GVHD(HR 2.98)和严重慢性GVHD(HR 3.60)与生存降低相关
  • 晚期死亡首位原因为复发,占49.0%

核心结论

  • allo-HSCT后无病生存2年患者的长期生存率良好,10年总生存率为91.9%(95%CI 89.8-93.5)。
  • 作者认为应实施策略以尽量减少受者晚期死亡相关风险。

研究设计与样本

  • 单中心队列研究,纳入2007至2019年在本中心因血液恶性肿瘤接受allo-HSCT并无病生存满2年的患者,共831例。
  • 508例(61.1%)接受单倍体相合供者移植。

主要发现

  • 10年总生存率为91.9%(95%CI 89.8-93.5)。
  • 既往III-IV级急性GVHD与生存降低相关(HR 2.98;95%CI 1.47-6.03;p=0.002),严重慢性GVHD与生存降低相关(HR 3.60;95%CI 1.93-6.71;p<0.001)。
  • 10年晚期复发概率为8.7%(95%CI 6.9-10.8),10年非复发死亡概率为3.6%(95%CI 2.5-5.1)。
  • 晚期死亡首位原因为复发,占49.0%。

临床怎么用

  • 作者建议应实施策略以尽量减少allo-HSCT后无病生存2年受者的晚期死亡相关风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most events that limit life expectancy after allogeneic haematopoietic stem cell transplantation (allo-HSCT) occur within the first 2 years; however, treatment outcomes in long-term survivors who survive for at least 2 years post-HSCT without relapse are yet to be elucidated. To explore the life expectancy trends and late complications and to assess the main mortality-related factors, we investigated the characteristics of patients who received allo-HSCT for haematological malignancies from 2007 to 2019 in our centre and survived in remission for 2 years. A cohort of 831 patients was enrolled; of these, 508 received grafts from haploidentical-related donors (61.1%). The estimated overall survival rate at 10 years was 91.9% (95% confidence interval [CI], 89.8-93.5), which was affected by prior grade III-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 2.98; 95% CI, 1.47-6.03; p = 0.002) and severe chronic GVHD (HR, 3.60; 95% CI, 1.93-6.71; p < 0.001). The probability of late relapse and non-relapse mortality at 10 years was 8.7% (95% CI, 6.9-10.8) and 3.6% (95% CI, 2.5-5.1) respectively. The top cause of late mortality was relapsed (49.0%). Projected long-term survival in 2-year disease-free survivors following allo-HSCT was excellent. Strategies should be implemented to minimise the late death-specific hazards in recipients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wu L, Wu Y, Shi J, et al. Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation. Br J Haematol. 2023. PMID: 37306071. doi:10.1111/bjh.18905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。